THE REPORT ON THE DRUG EFFICACY STUDY BY THE NAtional Research Council-National Academy of Sciences has been submitted to Commissioner Ley of the Food and Drug Administration and it is indeed an impressive document. Its "General Statements on the Use of Selected Categories of Drugs" would serve as excellent models for pharmacy and therapeutics committee action. On page 238 is the "Statement on the Use of Fixed Combinations of Antimicrobial Agents" which indicates the caliber of work done by this prestigious group.
The Drug Efficacy Study was conceived originally as an emergency measure to relieve the log jam in the FDA brought on by the decision of the Commissioner that the efficacy provisions of the 1962 Drug Amendments should be applied retroactively to all drugs that had been marketed from 1938 to 1962. This involved about 4000 formulations of approximately 300 distinct drugs and presented FDA's already overburdened staff with an overwhelming task.
In 1966, Dr. James Goddard, then Commissioner of FDA, requested the help of the Division of Medical Sciences of the National Academy of Sciences-National Research Council and his request was referred to the Drug Research Board. Sensitive to need and failing to identify any other organization that might more effectively tackle the task and mobilize the aid of the biomedical community, the Drug Research Board recommended approval of the request. A contract for $834,000 with the FDA was signed in June 1966 and was terminated in June 1969 when the flnal report was submitted.
The design and organization of the study was simple. A Policy Advisory Committee (PAC) was established to advise the Chairman of the Division of Medical Sciences of general policies and guidelines for the conduct of the study and on the selection of experts responsible for evaluating the efficacy of the drugs to be studied. The PAC consisted of 25 distinguished physicians and medical scientists whose caliber is reflected by the composition of its executive committee consisting of The entire area of drug usage was subdivided and 30 panels of about 185 experts were selected to evaluate drugs in each area. The chairmen and members of panels were appointed from among nominees recommended by the major professional and biomedical societies of the United States, The work of these panels of experts was supported by a professional staff of 13 headed by Mr. Duke C. Trexler who served as executive director. Serving as chairman of the PAC was Dr. William S. Middleton, Dean Emeritus of the School of Medicine, University of Wisconsin, who resigned in 1968 and was replaced by Dr. Alfred Gilman.
The informational base of the study was the manufacturer's package insert which is intended to provide the physician with adequate information on the composition, indications for use, effects, dosage and methods of administration together with relevant statements on hazards, contraindications, side effects and precautions. This and related information were collected by the FDA on 2824 drug preparations (representing about 4000 formulations) from about 240 manufacturers. About 15 percent of the drugs were over-the-counter items. Two • thirds were single entity drugs; 20 percent were combinations of two active ingredients and the balance contained more than two and some up to a dozen ingredients (vitamins).
The Drug Efficacy Study is an audit of the state of the art of drug usage which has pioneered new pathways for the future communication of drug information to health practitioners. I will discuss other aspects of the study in future issues.
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